Belite Bio Announces Participation at the 41st Asia-Pacific Academy of Ophthalmology Congress (APAO)

Monday’s market has seen swings in various stocks based on news and other factors. Today, stocks like Regencell Bioscience Holdings (RGC) are rallying, while stocks like AngloGold Ashanti Ltd (AU) are falling. Below are highlights of some of the biggest stock movers, from mega-caps to small caps.

Mega-Cap Movers ($200 billion USD or higher)

• Applovin (APP) -3.37%
• Alibaba-exch (BABA) -3.06%
• Tesla Motors (TSLA) -2.6%
• Micron Tech (MU) +2.1%

Large-Cap Stock Movers ($10-$200 billion USD)

• Regencell Bioscience Holdings (RGC) +19.28%
• AngloGold Ashanti Ltd (AU) -7.45%
• Agnico-Eagle Mines (AEM) -6.42%
• Newmont Mining (NEM) -5.8%
• Coeur dAlene Mines Corp (CDE) -4.59%
• Hecla Mining Comp (HL) -4.11%
• Coca-Cola Bottlin (COKE) -4.34%
• Royal Gold Inc. (RGLD) -3.96%
• Medline Inc (MDLN) -3.61%
• Lumentum Holdings Inc (LITE) -3.99%

Mid-Cap Stock Movers ($2-$10 billion USD)

• Ultragenyx (RARE); Ultragenyx’s bone disorder treatment fails primary endpoints in trials -44.6%
• Mudrick Capital A (HYMC) -11.15%
• Bellring Brands LLC (BRBR) -9.91%
• Aura Minerals NAQ (AUGO) -8.77%
• DRDGOLD Ltd (DRD) -8.76%
• Crocs (CROX) -6.35%
• MSCI Global Gold Miners Fund (RING) -6.73%
• Northstar At Mgt (DBRG); DigitalBridge Group (DBRG) halted following Softbank rumors +9.73%
• Belite Bio ADR (BLTE) +9.51%
• Praxis Precision Medicines Inc (PRAX); FDA grants breakthrough therapy designation for Praxis’s tremor drug +13.53%

Small-Cap Stock Movers ($300 million -$2 billion USD)

• Mereo BioPharma Group (MREO); Mereo’s setrusumab fails primary endpoint in osteogenesis imperfecta trials -87.5%
• Lionheart III (SMX) -31.59%
• Thunder Bridge Capital Partners IV (CNCK) -22.7%
• Cryptyde (ORBS); Eightco authorizes $125 million share buyback program +21.02%
• TryHard Holdings (THH) +29.32%
• Galena Biopharma (SLS); SELLAS reports 72 events in Phase 3 REGAL trial, awaits final analysis +18.29%
• Autolus Therapeutics (AUTL) +14.81%
• Neuralstem (PALI); Piper Sandler initiates Palisade Bio stock with Overweight rating on IBD drug +12.33%
• JATT Acquisition (ZURA) +11.29%
• Prime Acquisition (HPK) +9.6%

For real-time, market-moving news, join Investing Pro.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Investing.com -- Belite Bio Inc ADR (NASDAQ:BLTE) stock fell 2.4% in Monday’s after-hours trading after the clinical-stage drug development company announced plans for an underwritten public offering of American Depositary Shares (ADSs).

The company, which focuses on developing novel therapeutics for degenerative retinal diseases, said all securities in the offering will be sold by Belite Bio. The firm also intends to grant underwriters a 30-day option to purchase additional ADSs at the public offering price, less underwriting discounts and commission.

Belite Bio plans to use the proceeds for commercialization preparation, including building an in-house team and establishing sales networks, as well as for pipeline development and working capital. The offering is subject to market conditions, with no assurance regarding completion timing or terms.

Morgan Stanley & Co. LLC, Leerink Partners, BofA Securities, and Cantor are serving as joint active book-running managers for the offering.

The stock’s decline reflects typical market reaction to public offerings, which often lead to share dilution for existing stockholders.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Monday’s market has seen swings in various stocks based on news and other factors. Today, stocks like Alibaba and Micron Tech are rallying, while stocks like Shopify are falling. Below are highlights of some of the biggest stock movers, from mega-caps to small caps.

Mega-Cap Movers ($200B+ Market Cap)

• Micron Tech (MU) +2.13%
• Applovin (APP) +3.36%
• Alibaba-exch (BABA) +4.66%
• United Tech (RTX) -2.73%
• General Electric (GE) -2.69%
• Avago Technologies (AVGO) -3.16%
• Shopify Inc (SHOP) -3.61%

Large-Cap Stock Movers ($10B-$200B Market Cap)

• Astera Labs (ALAB) +9.36%
• Coherent (COHR) +6.66%
• Bitmine Immersion Tech (BMNR) -10.84%
• ETHA (ETHA) -9.44%
• MicroStrategy Inc (MSTR) -7.45%
• IBIT NASDAQ (IBIT) -6.18%
• FBTC NYSE (FBTC) -6.63%
• Bloom Energy Corp (BE) -6.05%
• SanDisk Corp-Exch (SNDK) -5.49%
• Moderna (MRNA) -5.99%

Mid-Cap Stock Movers ($2B-$10B Market Cap)

• Valeant Pharma (BHC); Bausch Health completes acquisition of Chinese aesthetics distributor +14.49%
• Ashland Inc (ASH) +11.73%
• Limited Brands (BBWI) +10.22%
• Belite Bio ADR (BLTE); Belite Bio’s tinlarebant shows 36% reduction in Stargardt disease lesions +9.45%
• BillionToOne (BLLN); BillionToOne stock initiated with Buy rating at Stifel on NIPT market share gains -13.83%
• MTech Acquisition A (ABTC) -9.79%
• FETH ETH (FETH) -9.77%
• Grail (GRAL) -8.99%
• Vaxcyte Inc (PCVX) -8.26%
• MER Telemanagemen (SBET) -8.8%

Small-Cap Stock Movers ($300M-$2B Market Cap)

• Thunder Bridge Capital Partners IV (CNCK) +123.15%
• Beyond Meat Inc (BYND) +23.24%
• Nexters (GDEV) +31.95%
• Leggett & Platt (LEG) +14.96%
• Columbus Circle Capital I (BRR) -41.38%
• ETHU (ETHU) -19.23%
• SOLT (SOLT) -18.15%
• Fast Acquisition Corp II (FBYD) -14.59%
• Learn CW Investment (INV) -11.78%
• BMNU (BMNU) +2.08%

For real-time, market-moving news, join Investing Pro.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Investing.com -- Belite Bio Inc ADR (NASDAQ:BLTE) stock jumped 17.1% in premarket trading Monday after announcing positive Phase 3 trial results for Tinlarebant, marking the first successful pivotal trial for Stargardt disease, a progressive vision loss condition with no currently approved treatments.

The company’s DRAGON trial met its primary efficacy endpoint, demonstrating a statistically significant 36% reduction in retinal lesion growth rate compared to placebo (p=0.0033). Stargardt disease affects more than 50,000 patients in the U.S. and has previously had no treatment options.

Tinlarebant was well-tolerated throughout the trial with only four treatment-related discontinuations. The most common drug-related ocular adverse events were xanthopsia and delayed dark adaptation, which were mostly mild and resolved during the trial.

"The final results from the DRAGON trial mark a historic breakthrough in Stargardt disease, paving the way for the first potential treatment for this devastating condition and bringing new hope to patients and families who have long faced a disease once considered untreatable," said Dr. Tom Lin, Chairman and CEO of Belite Bio.

The trial enrolled 104 patients aged 12-20 years with Stargardt disease type 1. In addition to the primary endpoint success, the treatment also showed a 33.6% lesion growth reduction in patients’ fellow eyes (p=0.041) and met key secondary endpoints.

Belite Bio plans to file a New Drug Application with the FDA in the first half of 2026. Tinlarebant has already received Breakthrough Therapy, Fast Track, and Rare Pediatric Disease Designations in the U.S., along with Orphan Drug Designation in the U.S., Europe, and Japan.

The company will host a conference call today at 8:00 a.m. ET to discuss the results.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.